Helping patients reclaim a life of possibility
The Israel Amyloidosis Association held its annual conference on 23 October 2026, bringing together approximately 200 patients, clinicians and researchers from across Israel. The event took place just ahead of World Amyloidosis Day on 26 October and featured presentations from leading Israeli experts in haematology, cardiology and neurology. Alongside a series of lectures and panel…
Myeloma Patients Europe (MPE) will host a webinar the “ International Symposium on Amyloidosis (ISA 2026) highlights”, on Wednesday, 25 November 2026 at 17:00 CET. During this webinar, you will learn about the latest research findings in AL amyloidosis presented at ISA 2026, held from 14 to 18 November 2026 in Montevideo, Uruguay and organised…
World Amyloidosis Day is 26 October. To mark the day, MPE is asking everyone in our community to download the MPE Amyloidosis Diagnosis Pathway and share it with their GP or family doctor. By helping primary care professionals recognise the signs and symptoms of AL amyloidosis earlier, we can play an important role in reducing…
The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis. Myeloma Patients Europe (MPE) will be attending EHA to keep…
The largest haematology meeting in the world has just finished. The American Society of Hematology (ASH) Annual Congress took place in Orlando, Florida, US, where the latest research in blood diseases was presented. Myeloma Patients Europe (MPE) interviewed key experts to learn more about the most relevant studies and abstracts in myeloma and AL amyloidosis.…
From 6-9 December Myeloma Patients Europe (MPE) attended the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Over 20,000 researchers, doctors, nurses and patient advocates attended the meeting to share and discuss the results of the latest research from across blood cancers. ASH was a great way to close out another successful year…
Prothena, the pharmaceutical company that produce the AL amyloidosis drug birtamimab, have announced that the Phase III AFFIRM-AL clinical trial failed to meet its primary endpoint – i.e., the main result being measured in the trial to determine whether the treatment was effective. This means that the trial failed to demonstrate that newly diagnosed AL…
Myeloma Patients Europe (MPE) will host a webinar on “Living well with AL amyloidosis” on Thursday, 5 June 2025 from 17:00 – 18:00 CEST. Aimed at AL amyloidosis patients and patient advocates, the webinar will feature presentations on supportive care for patients. Prof. Dr. Monique Minnema, Haematologist at the University Medical Centre Utrecht, will focus…